- Home
- INBX vs AUTL Comparison
INBX vs AUTL Comparison
Compare INBX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBX | AUTL |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.2M | 368.6M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | INBX | AUTL |
|---|---|---|
| Price | $76.74 | $1.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 236.0K | ★ 3.8M |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,400,000.00 | ★ $51,128,000.00 |
| Revenue This Year | $563.00 | $658.11 |
| Revenue Next Year | $230.77 | $91.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $10.81 | $1.11 |
| 52 Week High | $94.47 | $2.88 |
Technical Indicators
Market Signals| Indicator | INBX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 59.84 |
| Support Level | $79.00 | $1.46 |
| Resistance Level | $94.47 | $1.69 |
| Average True Range (ATR) | 5.90 | 0.10 |
| MACD | -2.08 | 0.03 |
| Stochastic Oscillator | 5.29 | 84.00 |
Price Performance
Historical ComparisonAbout INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.